Question Bank › Named catch-up gap

Named catch-up gap

Named catch-up gap: management identifies where the company visibly lags peers or its own potential, and is already clos

Calls Tested
500
Answered YES
24
Hit Rate
4.8%
rare by design

Regeneron Pharmaceuticals, Inc. (REGN) — this company's answers

NO on the Q4 2022 call 2023-02-03 C
The model's full reasoning — Q4 2022 call → NO1. The user asks to determine if management identifies a specific, named dimension on which the company currently underperforms relative to peers or its own potential, and describes work already underway to close that gap, with management treating it as a meaningful source of improvement not dependent on market conditions. 2. I need to scan the transcript for any such self-diagnosis of underperformance. 3. Let's look for keywords like "underperform", "lag", "gap", "shortfall", "weakness", "improve", "opportunity", "challenge", "issue". 4. In the transcript: - Len mentions "strong fourth quarter performance", "commercial strength", "increasing diversity". - Marion discusses EYLEA, Libtayo, DUPIXENT performance. She mentions "competitive pressures" but doesn't name a specific gap where Regeneron underperforms. - Bob discusses financials, guidance, R&D spend, SG&A spend. - George discusses pipeline progress. - There is a mention of "short-term shift earlier in the quarter where EYLEA was negatively impacted by a temporary increase in use of off-label compounded Avastin" and a "short-term closure of a not-for-profit patient co-pay assistance fund". This is a temporary external/market issue, not a self-identified structural underperformance gap. - There is no mention of a specific named dimension (e.g., "our international penetration is lower than peers", "our manufacturing yield is below industry standard", "our SG&A is too high relative to peers") where management says "we underperform here, and here is the work we are doing to fix it". - The closest thing to a gap is the EYLEA market share dip, but it's attributed to external factors (Avastin compounding, co-pay fund closure) and they say they "believe we have substantially recovered". This is not a self-diagnosed structural gap with work underway to close it; it's a temporary external shock. - There is no mention of a specific benchmark (e.g., "our margins are 10% lower than X") or a specific operational gap (e.g., "our sales force productivity is half of peers"). - The guidance for R&D and SG&A is just guidance, not a gap-closing narrative. 5. Let's check if any analyst question prompted such a response. The questions are about EYLEA competition, COPD data, oncology pipeline, etc. Management's responses don't adopt a "we underperform" narrative. 6.

← Back to the full REGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management IDENTIFY A SPECIFIC, NAMED DIMENSION ON WHICH THE COMPANY CURRENTLY UNDERPERFORMS — relative to industry peers, industry norms, or the company's own demonstrated potential elsewhere in its business — AND describe work ALREADY UNDERWAY to close that specific gap, with management treating the closing of it as a meaningful source of improvement that does not depend on market conditions getting better? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent self-diagnosis with both halves present: (1) A NAMED GAP, OWNED BY MANAGEMENT: management itself states, concretely, where the company lags — for example margins, productivity, utilization, pricing, mix, service levels, penetration of its own customer base, or performance of one region, segment, or facility versus the company's own better ones or versus what peers demonstrably achieve — identified specifically enough that a reader knows exactly what is deficient and roughly how large the shortfall is; and (2) CLOSING WORK IN MOTION WITH THE MECHANISM EXPLAINED: management describes the concrete actions already executing to close it — not aspirations — and conveys why the gap is closable by the company's own effort (the better level is already achieved by peers or by the company's own best operations, so the target is demonstrated rather than theoretical), with early progress or a credible operational path visible in the current period. Answer NO if management only claims general improvement opportunity without naming a specific measurable gap. NO if the gap is blamed on external conditions that must improve. NO if the closing work is only planned, promised, or under study. NO if the gap-closing is ordinary cost-cutting rhetoric with no named benchmark. NO if the diagnosis appears only in an analyst's question that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ASO Academy Sports and Outdoors, Inc. Q1 2024 2024-06-11 C+
MEG Montrose Environmental Group, Inc. Q3 2023 2023-11-08 C+
RVLV Revolve Group, Inc. Q3 2023 2023-11-01 C
CMG Chipotle Mexican Grill, Inc. Q3 2023 2023-10-27 B+
SWK Stanley Black & Decker, Inc. Q1 2023 2023-05-04 D
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
STC Stewart Information Services Corporation Q1 2022 2022-04-29 C+
KD Kyndryl Holdings, Inc. Q4 2021 2022-03-01 C+
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
HNRG Hallador Energy Company Q3 2021 2021-11-09 C+
LPTH LightPath Technologies, Inc. Q4 2021 2021-09-09 D
KOP Koppers Holdings Inc. Q2 2018 2018-08-12 C+
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
ACHC Acadia Healthcare Company, Inc. Q4 2017 2018-02-22 C+
ADNT Adient plc Q1 2018 2018-01-29 D
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
STKL SunOpta Inc. Q2 2017 2017-08-09 C+
PTC PTC Inc. Q3 2017 2017-07-19 C+
ABM ABM Industries Incorporated Q2 2017 2017-06-08 B
PPG PPG Industries, Inc. Q1 2017 2017-04-20 C
PDCO Patterson Companies, Inc. Q3 2017 2017-02-23 C
SXT Sensient Technologies Corporation Q4 2016 2017-02-10 A
BC Brunswick Corporation Q3 2016 2016-10-28 B+
SON Sonoco Products Company Q4 2015 2016-02-11 B

How the model reasoned

HOLX · Q4 2017 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management explicitly diagnosing Cynosure’s commercial organization as the specific underperforming dimension (salesforce turnover, recruiting, and productivity lagging behind the company’s international business and its own best operations). They then describe concrete, already-executing actions—stopping voluntary turnover, rehiring high performers, instituting 90-day reviews, new compensation, and building “Cynosure 2.0”—as the mechanism to close the gap.
STKL · Q2 2017 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management identifying a specific named gap in the bars segment, where operational issues at a particular facility are causing inefficient production and gross margin losses. They describe a rapid recovery team already executing systematic identification and correction of these issues, treating the gap as closable through their own operational efforts rather than external market improvements — this aligns with the criteria for a meaningful source of improvement.
ADNT · Q1 2018 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management explicitly naming the Seat Structures and Mechanisms (SS&M) business as the specific underperforming dimension. They state it is “destroyed shareholder value” when run as currently organized, and that it is “impacting our financial results” with “significant impact.

More from the question bank

Paid to expand: the company's growth spendinThe product is disappearing into reorder rhyRecently unlocked doorWorking for customers it could not have servVolume records through a still-fixed gateTwo-sided intensityAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.